WHO ICTRP trial
Bioequivalence study of Atorvastatin 20 mg tablet
IRCT20210519051345N61 · Iranian Registry of Clinical Trials (IRCT) · Recruiting
Key facts
| Trial ID | IRCT20210519051345N61 |
|---|---|
| Public title | Bioequivalence study of Atorvastatin 20 mg tablet |
| Scientific title | Fasted-state in vivo bioequivalence study of Atorvastatin 20 mg tablet manufactured by Sobhan Darou Co. compared with innovator product |
| Primary sponsor | Tabriz University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Recruiting |
| Study type | interventional |
| Phase | Bioequivalence |
| Countries | Iran (Islamic Republic of) |
| Conditions | In the present study, the products will be administered to healthy volunteers. |
| Interventions | Intervention 1: Intervention group: Intervention group will receive a single oral dose of test product (Atorvastatin 20 mg tablet manufactured by Sobhan Darou Co.) in fasted state. Blood samples will be collected for 48 hours at the… |
| Registration date | Jun 8, 2024 |
| Target size | 24 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: